Literature DB >> 3318057

The ultrastructure and immunocytochemistry of renal cell carcinoma.

B Mackay1, N G Ordónez, J Khoursand, J L Bennington.   

Abstract

The spectrum of ultrastructural features of a series of primary renal cell adenocarcinomas, including clear cell, granular, oncocytic, and sarcomatoid types, and a group of metastatic renal cell adeno-carcinomas has been studied. The contributions of electron microscopy and immunocytochemistry as adjuncts to light microscopy and histochemistry in the differential diagnosis of metastatic renal cell adenocarcinoma in various anatomic locations are reviewed.

Entities:  

Mesh:

Year:  1987        PMID: 3318057     DOI: 10.3109/01913128709048445

Source DB:  PubMed          Journal:  Ultrastruct Pathol        ISSN: 0191-3123            Impact factor:   1.094


  5 in total

1.  Eosinophilic cytoplasmic inclusions in papillary renal cell carcinoma.

Authors:  Naoyuki Danbara; Nobuaki Shikata; Hiroshi Kawamura; Masayuki Shintaku; Airo Tsubura
Journal:  Med Mol Morphol       Date:  2005-12       Impact factor: 2.309

Review 2.  Misdiagnosis of clear cell renal cell carcinoma.

Authors:  Vladimir A Valera; Maria J Merino
Journal:  Nat Rev Urol       Date:  2011-05-17       Impact factor: 14.432

3.  Ultrastructural appearance and cytoskeletal architecture of the clear, chromophilic, and chromophobe types of human renal cell carcinoma in vitro.

Authors:  C D Gerharz; R Moll; S Störkel; U Ramp; W Thoenes; H E Gabbert
Journal:  Am J Pathol       Date:  1993-03       Impact factor: 4.307

4.  Expression of MUC1 mucins inversely correlated with post-surgical survival of renal cell carcinoma patients.

Authors:  K Fujita; K Denda; M Yamamoto; T Matsumoto; M Fujime; T Irimura
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

5.  Stem/progenitor cell marker expression in clear cell renal cell carcinoma: a potential relationship with the immune microenvironment to be explored.

Authors:  Ju-Yoon Yoon; Craig Gedye; Joshua Paterson; Laurie Ailles
Journal:  BMC Cancer       Date:  2020-04-03       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.